Alkermes Plc (NASDAQ:ALKS) saw a large decline in short interest in February. As of February 28th, there was short interest totalling 10,070,647 shares, a decline of 14.5% from the February 15th total of 11,774,329 shares. Currently, 6.7% of the shares of the stock are short sold. Based on an average daily trading volume, of 1,345,512 shares, the short-interest ratio is currently 7.5 days.
In other news, Director Paul J. Mitchell sold 1,000 shares of the business’s stock in a transaction on Thursday, March 1st. The stock was sold at an average price of $57.04, for a total transaction of $57,040.00. Following the completion of the transaction, the director now owns 9,000 shares of the company’s stock, valued at approximately $513,360. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Mark Stejbach sold 10,880 shares of the business’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $70.50, for a total value of $767,040.00. Following the transaction, the senior vice president now directly owns 54,893 shares of the company’s stock, valued at approximately $3,869,956.50. The disclosure for this sale can be found here. Insiders have sold a total of 125,433 shares of company stock valued at $7,942,327 in the last three months. 5.34% of the stock is owned by insiders.
A number of institutional investors and hedge funds have recently modified their holdings of ALKS. SG Americas Securities LLC acquired a new stake in shares of Alkermes in the fourth quarter valued at about $114,000. Quantbot Technologies LP acquired a new stake in shares of Alkermes in the third quarter valued at about $126,000. Virtu Financial LLC acquired a new stake in shares of Alkermes in the third quarter valued at about $201,000. M&T Bank Corp acquired a new stake in shares of Alkermes in the fourth quarter valued at about $221,000. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in shares of Alkermes in the third quarter valued at about $214,000.
Alkermes (ALKS) opened at $60.35 on Wednesday. Alkermes has a fifty-two week low of $46.42 and a fifty-two week high of $71.22. The company has a debt-to-equity ratio of 0.23, a current ratio of 2.78 and a quick ratio of 2.46. The stock has a market capitalization of $9,280.00, a PE ratio of -64.20 and a beta of 1.87.
Alkermes (NASDAQ:ALKS) last issued its earnings results on Wednesday, February 14th. The company reported $0.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.32. Alkermes had a negative return on equity of 4.32% and a negative net margin of 17.48%. The business had revenue of $275.37 million during the quarter, compared to analysts’ expectations of $251.23 million. During the same quarter in the prior year, the firm earned $0.02 EPS. The business’s revenue for the quarter was up 29.0% compared to the same quarter last year. equities analysts forecast that Alkermes will post -0.8 earnings per share for the current year.
A number of equities analysts have recently commented on ALKS shares. ValuEngine raised Alkermes from a “sell” rating to a “hold” rating in a report on Friday, December 1st. Credit Suisse Group boosted their price target on Alkermes from $66.00 to $70.00 and gave the stock an “outperform” rating in a report on Friday, February 16th. Jefferies Group cut Alkermes from a “buy” rating to a “hold” rating and upped their target price for the stock from $63.19 to $66.00 in a report on Thursday, February 22nd. BidaskClub cut Alkermes from a “hold” rating to a “sell” rating in a report on Saturday, January 20th. Finally, Zacks Investment Research raised Alkermes from a “hold” rating to a “buy” rating and set a $71.00 target price for the company in a report on Monday, February 5th. Nine equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $64.58.
TRADEMARK VIOLATION NOTICE: This report was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://ledgergazette.com/2018/03/14/alkermes-plc-alks-short-interest-update.html.
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.